Table 1 Clinical characteristics of the 82 kidney transplant recipients.
From: Booster effect of the third dose of SARS-CoV-2 mRNA vaccine in Japanese kidney transplant recipients
Variable | Total (N = 82) |
|---|---|
Age, year | 53.5 ± 11.6 |
Sex, male, n (%) | 53 (64.6) |
Body mass index, kg/m2 | 22.7 ± 3.5 |
Time post last transplantation, year | 10.6 (4.0 to 16.2) |
First transplant, n (%) | 79 (96.3) |
Donor type, living, n (%) | 73 (89.0) |
Donor age, year | 57.5 (49 to 64) |
Donor sex, male, n (%) | 28 (36.4) |
Primary kidney disease | |
IgA nephrology | 27 (32.9) |
FSGS | 7 (8.5) |
Diabetes mellitus | 4 (4.9) |
Others | 44 (53.7) |
ABO incompatible, n (%) | 13 (15.9) |
HLA class I mismatch | 1.7 ± 0.9 |
HLA class II mismatch | 0.9 ± 0.5 |
Rituximab use, n (%) | 24 (29.3) |
Methylprednisolone use, n (%) | 68 (82.9) |
Tacrolimus use, n (%) | 71 (86.6) |
Mycophenolic acid use, n (%) | 74 (90.2) |
Mycophenolic acid dose, mg/day | 978.7 ± 441.3 |
Methylprednisolone + Tacrolimus + Mycophenolic acid, n (%) | 58 (70.7) |
Hemoglobin, g/dL | 13.1 ± 2.0 |
Lymphocyte, /μL | 1498.8 ± 668.6 |
Albumin, g/dL | 4.2 ± 0.3 |
Serum creatinine, mg/dL | 1.2 (1.0 to 1.7) |
eGFR, mL/min/m2 | 44.9 ± 17.1 |
TSAT, % | 32.6 ± 11.9 |
Ferritin, ng/mL | 119 (57 to 198) |
25(OH)D, ng/mL | 14.9 (10.6 to 21.3) |
Iron drug use, n (%) | 13 (15.9) |
1α-OH-D3 drug use, n (%) | 33 (40.2) |
Hypertension, n (%) | 56 (68.3) |
Diabetes mellitus, n (%) | 21 (25.6) |
ACE-I or ARB use, n (%) | 47 (57.3) |
Rejection, n (%) | 21 (25.6) |
Twice Vaccine type, BNT162b2 vs mRNA-1273, n (%) | 70 (85.4) vs 12 (14.6) |
Third Vaccine type, BNT162b2 vs mRNA-1273, n (%) | 43 (52.4) vs 39 (47.6) |
